Chimeric antigen receptor
AssigneesUniversite De Geneve, Les Hopitaux Universitaires De Geneve
InventorsDenis MIGLIORINI, Valérie DUTOIT, Pierre-Yves DIETRICH, Darel MARTINEZ BEDOYA
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a chimeric antigen receptors (CARs) specific for one or more glioma-associated antigens and an immune effector cell or a population of immune effector cells expressing one or more CARs specific for one or more glioma-associated antigens. The disclosure also relates to a method of making the immune cell or population, a method of treating cancer using the immune cell or population.
Claims37
An immune effector cell or a population of immune effector cells expressing:
- (a) one or more chimeric antigen receptors (CARs) specific for two or more glioma-associated antigens, wherein one or more of the glioma-associated antigens are selected from PTPRZ1, BCAN, CSPG4 and TNC;
- (b) a chimeric antigen receptor (CAR) specific for PTPRZ1;
- or
- (c) a chimeric antigen receptor (CAR) specific for BCAN.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A CAR that is:
- (i) specific for PTPRZ1;
- (ii) specific for BCAN;
- (iii) specific for a glioma associated antigen selected from PTPRZ1, BCAN, CSPG4 and TNC, comprising a polypeptide comprising:
- (a) the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from an amino acid sequence selected from any one of SEQ ID NOs:
- 21-40;
- or
- (b) the complementary determining regions (CDR1, CDR2 and CDR3) from an amino acid sequence selected from any one of SEQ ID NOs:
- 83-93;
- or
- (iv) multivalent and which comprises (a) an extracellular domain specific for two or more glioma-associated antigens, wherein one or more of the glioma-associated antigens are selected from PTPRZ1, BCAN, CSPG4 and TNC;
- and (b) and an intracellular signalling domain.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An antigen binding molecule specific for one or more glioma-associated antigens, which comprises a polypeptide comprising the complementary determining regions (CDR1, CDR2 and CDR3) from an amino acid sequence selected from any one of SEQ ID NOs:
- 83-93;
- optionally wherein the polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to the amino acid sequence of any one of SEQ ID NOs:
- 21-40 and 83-93.
(canceled)
Dependencies are inferred from the claim text.